Phaseline

Targets › ADRA1B

ADRA1B (Alpha-1B adrenergic receptor): drug programs, companies and trials

28 programs from 27 companies in 49 trials: 17 Phase 4, 12 Phase 2, 11 Phase 3, 9 Phase 1; Other, Cardiovascular, Neurology; next expected readout Dec 2026.

Alpha-1 adrenergic receptors are G protein-coupled receptors for catecholamines that signal through the G(q) family of G proteins, including G(q) and G(11). Upon activation, they stimulate the phosphatidylinositol-calcium second messenger pathway, leading to calcium release from intracellular stores and activation of protein kinase C (By similarity). (UniProt, P35368)

Open in Phaseline: the race on ADRA1B, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University of ChicagoPhenylephrine
Adrenergic receptor alpha-1 agonist
ADRA1A, ADRA1D, ADRA1BPhase 4ShockDec 2026
Sohag UniversityPhenylephrine
Adrenergic receptor alpha-1 agonist
ADRA1A, ADRA1D, ADRA1BPhase 4Patients Undergoing Orthopedic Hip Surgery Under Spinal AnesthesiaMar 2027
University of AlbertaMidodrine
Adrenergic receptor alpha-1 agonist
ADRA1A, ADRA1D, ADRA1BPhase 4VasoplegiaMar 2027
James J. Peters Veterans Affairs Medical CenterMidodrine Hydrochloride
Adrenergic receptor alpha-1 agonist
ADRA1A, ADRA1D, ADRA1BPhase 4HypotensionJun 2027
Seoul National University HospitalPhenoxybenzamine
Adrenergic receptor alpha antagonist
ADRA1A, ADRA2A, ADRA2C, ADRA1D, ADRA1BPhase 4PheochromocytomaAug 2027
University of AlbertaPhenylephrine
Adrenergic receptor alpha-1 agonist
ADRA1A, ADRA1D, ADRA1BPhase 4VasoconstrictionDec 2027
Dalian Municipal Central HospitalPhenylephrine
Adrenergic receptor alpha-1 agonist
ADRA1A, ADRA1D, ADRA1BPhase 4Hypotension Drug-Induced–
Rawalpindi Medical CollegePhenylephrine
Adrenergic receptor alpha-1 agonist
ADRA1A, ADRA1D, ADRA1BPhase 4Phenylephrine–
Hassan II UniversityPhenylephrine
Adrenergic receptor alpha-1 agonist
ADRA1A, ADRA1D, ADRA1BPhase 4Cesarean Section Complications–
VA Office of Research and DevelopmentPrazosin
Adrenergic receptor alpha-1 antagonist
ADRA1A, ADRA1D, ADRA1BPhase 3Posttraumatic Stress DisorderDec 2026
Bir HospitalTamsulosin Hydrochloride
Adrenergic receptor alpha-1 antagonist
ADRA1A, ADRA1D, ADRA1BPhase 3Ureteral Stent-Related SymptomDec 2026
Penang Hospital, MalaysiaTerazosin
Adrenergic receptor alpha-1 antagonist
ADRA1A, ADRA1D, ADRA1BPhase 3Stent Related SymptomsMay 2027
CHU de Quebec-Universite LavalTamsulosin hydrochloride
Adrenergic receptor alpha-1 antagonist
ADRA1A, ADRA1D, ADRA1BPhase 3Urinary RetentionJul 2027
Opus GeneticsPhentolamine Ophthalmic Solution 0.75%
Non-selective alpha-1 and alpha-2 adrenergic antagonist
ADRA1A, ADRA1B, ADRA1D, ADRA2APhase 3Vision Loss Night; Insulin ResistanceAug 2027
University College, LondonTerazosin
Adrenergic receptor alpha-1 antagonist
ADRA1A, ADRA1D, ADRA1BPhase 3Parkinsons Disease (PD)May 2031
Cairo UniversityOraVerse (phentolamine mesylate)
Alpha-adrenergic antagonist and vasodilator that reverses local anesthetic effects by bloc
ADRA1A, ADRA1BPhase 3Soft Tissue Injuries–
Santen SASOxymetazoline (STN1013800)
Adrenergic receptor alpha agonist
ADRA1A, ADRA2A, ADRA2C, ADRA1D, ADRA1BPhase 3Acquired Blepharophimosis; Sleep Apnea; Perioperative Respiratory Adverse Events; Nasal Obstruction–
Brown UniversityDoxazosin
Adrenergic receptor alpha-1 antagonist
ADRA1A, ADRA1D, ADRA1BPhase 2Alcohol Use Disorder (AUD)Dec 2026
University of Wisconsin, MadisonPrazosin
Adrenergic receptor alpha-1 antagonist
ADRA1A, ADRA1D, ADRA1BPhase 2Magnetic Resonance ImagingMay 2027
University of AarhusPhenylephrine
Adrenergic receptor alpha-1 agonist
ADRA1A, ADRA1D, ADRA1BPhase 2HypotensionDec 2027
Ottawa Heart Institute Research CorporationMidodrine
Adrenergic receptor alpha-1 agonist
ADRA1A, ADRA1D, ADRA1BPhase 2Heart Failure With Reduced Ejection FractionJun 2028
Cedars-Sinai Medical CenterTerazosin
Adrenergic receptor alpha-1 antagonist
ADRA1A, ADRA1D, ADRA1BPhase 2REM Sleep Behavior Disorder; Symptomatic Parkinson Disease–
Shaheed Mohtarma Benazir Bhutto Institue of TraumaXylometazoline nasal drops 0.1%
Alpha-1 and alpha-2 adrenergic agonist for vasoconstriction
ADRA1A, ADRA1B, ADRA2APhase 2Nasal Bleeding–
Kingston Health Sciences Centrephenylephrine
Adrenergic receptor alpha-1 agonist
ADRA1A, ADRA1D, ADRA1BPhase 2Shock–
University of ManitobaPhenylephrine
Adrenergic receptor alpha-1 agonist
ADRA1A, ADRA1D, ADRA1BPhase 1Blood Loss, SurgicalJun 2028
Montefiore Medical CenterPhenylephrine
Adrenergic receptor alpha-1 agonist
ADRA1A, ADRA1D, ADRA1BPhase 1Mitral Regurgitation–
Berlin-Chemie AG Menarini GroupTamsulosin
Adrenergic receptor alpha-1 antagonist
ADRA1A, ADRA1D, ADRA1BPhase 1Healthy Volunteers; Healthy Adult Males Volunteers; Healthy Volunteer Male Subjects; Nephrolithiasis …–
University of IowaTerazosin
Adrenergic receptor alpha-1 antagonist
ADRA1A, ADRA1D, ADRA1BPhase 1Healthy–

Conditions

Stent Related Symptoms (2) Urinary Retention (2) Hypotension (2) Phenylephrine (2) Magnetic Resonance Imaging (2) Shock (2) Parkinsons Disease (PD) (1) REM Sleep Behavior Disorder (1) Symptomatic Parkinson Disease (1) Pheochromocytoma (1) Ureteral Stent-Related Symptom (1) Vasoplegia (1)

Modalities

small molecule (27)

Companies

University of Alberta (2) University College, London (1) Cedars-Sinai Medical Center (1) Seoul National University Hospital (1) Bir Hospital (1) Santen SAS (1) Berlin-Chemie AG Menarini Group (1) Brown University (1) James J. Peters Veterans Affairs Medical Center (1) Shaheed Mohtarma Benazir Bhutto Institue of Trauma (1) University of Iowa (1) Ottawa Heart Institute Research Corporation (1) Dalian Municipal Central Hospital (1) Sohag University (1) Rawalpindi Medical College (1) University of Aarhus (1) VA Office of Research and Development (1) University of Manitoba (1) University of Wisconsin, Madison (1) University of Chicago (1)

Related targets

ADRA1A (28) ADRA1D (26) ADRA2A (4) ADRA2C (2)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.